Origins (EPIC 2) Inclusion Criteria

  • Able and willing to participate and sign an informed consent and HIPAA form
  • Males or females, aged 18 to < 55 at time of consent
  • EDSS of between 0 and 7.5
  • Willingness to return for each scheduled visit
  • A suspected diagnosis of MS, CIS, RIS or other neurological disorder event suggesting an MS relapse
    • Age ≤ 40: within 90 days of suspected inflammatory disease activity
    • Age 41-55: current inflammatory disease activity at time of enrollment
  • No prior treatment with MS disease modifying therapies or board spectrum immune suppressants
  • No treatment with corticosteroids within the last 30 days
  • Must be willing to undergo at least one lumbar puncture (at baseline)

Origins (EPIC 2) Exclusion Criteria

  • Subjects receiving corticosteroids for any reason within 30 days of screening. If non-systemic steroids are being used for other chronic inflammatory conditions, subjects may be included at the discretion of the investigator.
  • Subjects participating in ongoing clinical trials with non-approved drugs at entry
  • Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months
  • Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may prevent the subject from safely completing the assessments required by the protocol
  • Unable to give consent
  • For neuroimaging studies additional exclusion criteria are:
    • Individuals who are unable to undergo an MRI due to metal implants
    • Women who are pregnant
    • Some other condition which would prevent them from undergoing and MRI (ie: a patient who had kidney disease and was unable to be administered gadolinium contrast dye)

Microbiome Exclusion Criteria

Individuals that have a GI infection and/or are taking or have taken any kind of antibiotic drugs in the previous 12 weeks.

CSF Exclusion Criteria

Individuals with known disorders of the blood-clotting system and those that are taking blood thinners (ex: Coumadin).